Topiramate Liquid Formulation Solubility via Composite Solvents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liquid pharmaceutical formulations of topiramate exhibit limited solubility in polyethylene glycol (PEG) 400 and glycerol, which restricts the maximum concentration of topiramate that can be maintained in a solution phase, limiting their therapeutic efficacy and administration efficiency.
Innovation Solution
Formulations comprising specific proportions of topiramate, PEG 400, and glycerol, with optional additives like sweeteners and flavorants, are developed to enhance solubility, allowing for higher concentrations of topiramate (up to 70 mg/ml) by heating the mixture to achieve a clear solution, thereby surpassing prior-art solubility limits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If topiramate is formulated in PEG 400 and glycerol, then the formulation can be prepared with simple ingredients, but the solubility of topiramate is limited to low concentrations
Solution Approach 1:
The patent applies parameter changes by modifying the physical state and temperature parameters during formulation. Specifically, the formulation is prepared at elevated temperatures (e.g., heating to dissolve topiramate) and then cooled to room temperature, which changes the solubility parameters and enables higher concentrations of topiramate to remain in solution phase.
Solution Approach 2:
The patent uses a composite solvent system combining PEG 400 and glycerol in specific ratios (e.g., 1:4, 1:3, 1:2, or 1:1 weight ratios) to achieve synergistic solubility enhancement. This composite material approach allows the formulation to exceed the solubility limits of individual solvents and maintain stable high concentrations of topiramate.
2Quantity of substance
If heating is applied to increase topiramate solubility, then higher concentrations can be achieved, but the formulation process becomes more complex
Solution Approach 1:
The patent exploits phase transitions by heating the formulation to transition topiramate from undissolved solid to dissolved state, then cooling to room temperature to maintain the high concentration in solution phase. This controlled phase transition approach enables high solubility without requiring complex equipment, simply using temperature cycling.
3Quantity of substance
If higher concentrations of topiramate are formulated, then therapeutic efficacy is improved, but the risk of precipitation and formulation instability increases
Solution Approach 1:
The patent employs a composite solvent system of PEG 400 and glycerol in optimized ratios that provide synergistic solubility enhancement. This composite material creates a stable molecular environment that prevents precipitation even at high topiramate concentrations (e.g., 50-100 mg/ml), maintaining formulation stability through the combined solvation capabilities of both solvents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enhanced solubility of topiramate in these formulations enables effective treatment of various conditions, including seizures and neurological disorders, by maintaining high concentrations of the active ingredient in a stable solution phase, improving therapeutic outcomes.
Implementation Method 1
by heating the mixture to achieve a clear solution
Implementation Method 2
the solubility of topiramate in these formulations enables effective treatment... by maintaining high concentrations of the active ingredient in a stable solution phase
Data Source
AI summary
Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of topiramate that is from 50 mg/ml to 100 mg/ml and amounts of polyethylene glycol (“PEG”) 400 and glycerol sufficient to result in a greater than a prior art taught calculated maximum amount of the topiramate being in the solution phase of the formulation, at room temperature.